

But E2
D
9. (Amended) A process for preparing serine protease, domain or their partial peptides comprising culturing or breeding a non-human host cell as claimed in claim 8, and recovering serine protease, domain or their partial peptides.

But E3
D
14. (Amended) DNA which codes for the serine protease, domain or their partial peptides as claimed in claim 22.

15. (Amended) DNA which codes for the serine protease, domain or their partial peptide as claimed in claim 23.

16. (Amended) DNA which codes for the serine protease, domain or their partial peptide as claimed in claim 24.

Please add new claims 21-59 as follows:

But E4
D
--21. A serine protease or its partial peptide consisting of an amino acid sequence selected from the group consisting of: the amino acid sequence indicated in SEQ ID NO: 6; an amino acid sequence wherein at least one amino acid residue in an amino acid sequence shown in SEQ ID NO: 6 is deleted; an amino acid sequence wherein at least one amino acid residue in amino acid sequence shown in SEQ ID NO: 6 is substituted with at least one other amino acid; an amino acid sequence wherein at least one amino acid is added to the amino acid sequence shown in SEQ ID NO: 6; and an amino acid sequence including a combination of said amino acid modifications.

22. A serine protease domain or its partial peptide consisting of an amino acid sequence selected from the group consisting of: the amino acid sequence from amino acid No. 578 to 822 indicated in SEQ ID NO: 6; an amino acid sequence wherein at least one amino acid residue in an amino acid sequence from amino acid No. 578 to 822 indicated in

SEQ ID NO: 6 is deleted; an amino acid sequence wherein at least one amino acid residue in an amino acid sequence from amino acid No. 578 to 822 indicated in SEQ ID NO: 6 is substituted with at least one other amino acid; an amino acid sequence wherein at least one amino acid is added to the amino acid sequence shown in SEQ ID NO: 6; and an amino acid sequence including a combination of said amino acid modifications.

23. A kringle domain or its partial peptide consisting of an amino acid sequence selected from the group consisting of: the amino acid sequence from amino acid No. 40 to 112 indicated in SEQ ID NO: 6; an amino acid sequence wherein at least one amino acid residue in an amino acid sequence from amino acid No. 40 to 112 indicated in SEQ ID NO: 6 is deleted; an amino acid sequence wherein at least one amino acid residue in an amino acid sequence from amino acid No. 40 to 112 indicated in SEQ ID NO: 6 is substituted with at least one other amino acid; an amino acid sequence wherein at least one amino acid is added to the amino acid sequence shown in SEQ ID NO: 6; and an amino acid sequence including a combination of said amino acid modifications.

24. A scavenger receptor cystein-rich (SRCR) domain or its partial peptide consisting of an amino acid sequence selected from the group consisting of: the amino acid sequence from amino acid No. 117 to 217, from amino acid No. 227 to 327, from amino acid No. 334 to 433, or from amino acid No. 447 to 547 indicated in SEQ ID NO: 6; an amino acid sequence wherein at least one amino acid residue in an amino acid sequence from amino acid No. 117 to 217, from amino acid No. 227 to 327, from amino acid No. 334 to 433, or from amino acid No. 447 to 547 indicated in SEQ ID NO: 6 is substituted with at least one other amino acid; an amino acid sequence wherein at least one amino acid is added to the amino acid sequence shown in SEQ ID NO: 6; and an amino acid sequence including a combination of said amino acid modifications.

25. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substances using the serine protease or their partial peptides as claimed in claim 21, or measuring binding affinity of the substances to the serine protease or domain as claimed in claim 21.

26. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the serine protease or their partial peptides as claimed in claim 21, or measuring binding affinity of the substance to the serine protease or their partial peptides as claimed in claim 21, that is prepared by using a DNA which codes for the serine protease, domain or their partial peptides as claimed in claim 21.

27. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the serine protease or their partial peptides as claimed in claim 21, or measuring binding affinity of the substance to the serine protease or their partial peptides as claimed in claim 21, that is prepared by using a DNA which codes for a peptide having serine protease, domain or their partial peptide activity, and is hybridizable with DNA that codes for the serine protease, domain or their partial peptides as claimed in claim 21 under stringent conditions.

28. An isolated DNA which codes for a peptide having domain or their partial peptide activity, and is hybridizable with DNA that codes for the domain or their partial peptides as claimed in claim 22, under stringent conditions.

29. An isolated DNA which codes for a peptide having domain or their partial peptide activity, and is hybridizable with DNA that codes for the domain or their partial peptides as claimed in claim 23, under stringent conditions.

Sub E4
30. An isolated DNA which codes for a peptide having domain or their partial peptide activity, and is hybridizable with DNA that codes for the domain or their partial peptides as claimed in claim 24, under stringent conditions.

31. An expression vector containing the DNA as claimed in claim 14.

32. An expression vector containing the DNA as claimed in claim 15.

33. An expression vector containing the DNA as claimed in claim 16.

TX
34. An expression vector containing the DNA as claimed in claim 28.

35. An expression vector containing the DNA as claimed in claim 29.

36. An expression vector containing the DNA as claimed in claim 30.

37. A host cell transformed by the expression vector as claimed in claim 31.

38. A host cell transformed by the expression vector as claimed in claim 32.

39. A host cell transformed by the expression vector as claimed in claim 33.

40. A host cell transformed by the expression vector as claimed in claim 12.

41. A host cell transformed by the expression vector as claimed in claim 34.

42. A host cell transformed by the expression vector as claimed in claim 35.

43. A host cell transformed by the expression vector as claimed in claim 36.

44. A process for preparing domain or their partial peptides comprising culturing or breeding a non-human host cell as claimed in claim 37, and recovering domain or their partial peptides.

45. A process for preparing domain or their partial peptides comprising culturing or breeding a non-human host cell as claimed in claim 38, and recovering domain or their partial peptides.

46. A process for preparing domain or their partial peptides comprising culturing or breeding a non-human host cell as claimed in claim 39, and recovering domain or their partial peptides.

47. A process for preparing serine protease or their partial peptides comprising culturing or breeding a non-human host cell as claimed in claim 40, and recovering serine protease or their partial peptides.

48. A process for preparing domain or their partial peptides comprising culturing or breeding a non-human host cell as claimed in claim 41, and recovering domain or their partial peptides.

49. A process for preparing domain or their partial peptides comprising culturing or breeding a non-human host cell as claimed in claim 42, and recovering domain or their partial peptides.

50. A process for preparing domain or their partial peptides comprising culturing or breeding a non-human host cell as claimed in claim 43, and recovering domain or their partial peptides.

Sub ES
51. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain or their partial peptides as claimed in claim 22, or measuring binding affinity of the substance to the domain or their partial peptides as claimed in claim 22.

D4
52. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain or their partial peptides as claimed in claim 23, or measuring binding affinity of the substance to the domain or their partial peptides as claimed in claim 23.

53. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain or their partial peptides as claimed in claim 24, or measuring binding affinity of the substance to the domain or their partial peptides as claimed in claim 24.

54. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain or their partial peptides as claimed in claim 22, or measuring binding affinity of the substance to the domain or their partial peptides as claimed in claim 22, that prepared by using the DNA which codes for the serine protease, domain or their partial peptides as claimed in claim 22.

55. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain or

their partial peptides as claimed in claim 23, or measuring binding affinity of the substance to the domain or their partial peptides as claimed in claim 23, that prepared by using the DNA which codes for the serine protease, domain or their partial peptide as claimed in claim 23.

56. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain or their partial peptides as claimed in claim 24, or measuring binding affinity of the substance to the domain or their partial peptides as claimed in claim 24, that prepared by using the DNA which codes for the serine protease, domain or their partial peptide as claimed in claim 24.

57. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain or their partial peptides as claimed in claim 22, or measuring binding affinity of the substance to the domain or their partial peptides as claimed in claim 22, that prepared by using the DNA which codes for a peptide having domain or their partial peptide activity, and is hybridizable with DNA that codes for the domain or their partial peptides as claimed in claim 22, under stringent conditions.

58. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain or their partial peptides as claimed in claim 23, or measuring binding affinity of the substance to the domain or their partial peptides as claimed in claim 23, that prepared by using the DNA which codes for a peptide having domain or their partial peptide activity, and is hybridizable with DNA that codes for the domain or their partial peptides as claimed in claim 23, under stringent conditions.

59. A process for screening physiologically active substances comprising the steps of measuring inhibitory or activating activity of the substance using the domain or their partial peptides as claimed in claim 24, or measuring binding affinity of the substance to the domain or their partial peptides as claimed in claim 24, that prepared by using the DNA which codes for a peptide having domain or their partial peptide activity, and is hybridizable with DNA that codes for the domain or their partial peptides as claimed in claim 24, under stringent conditions.--